{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:36:21Z","timestamp":1792136181715,"version":"4.4.0"},"reference-count":14,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda","doi-asserted-by":"publisher","award":["This study was supported by an unrestricted institutional grant from Takeda"],"award-info":[{"award-number":["This study was supported by an unrestricted institutional grant from Takeda"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Background: The global incidence of dengue has markedly increased over the last decades. Consequently, the risk of infection has increased significantly, resulting in record numbers of imported cases in various European countries and elsewhere in 2024. Methods: In early 2023, TAK-003, a novel, live attenuated vaccine against dengue, became available in Germany. At the Berlin Centre for Travel &amp; Tropical Medicine, we delivered 56,459 doses during the first 24 months of its availability, from February 2023 to February 2025. To obtain data on the tolerability of the vaccine in travelers, an active follow-up survey was initiated. Results: In total, 30,306 (53.7%) vaccinees agreed to being contacted. Of these, 11,827 (39.0%) completed an anonymous questionnaire \u2265 4 weeks after the vaccination. Overall, 6856 (58.0%) were female, and 565 (4.8%) reported having had a prior dengue infection. The average age was 38.3 years (range 4\u201386 years). An endemic area had been visited by 6309 subjects before answering the questionnaire, and among these, 46 (0.7%) reported a dengue infection while abroad. All cases were mild, and no complications were reported. TAK-003 was applied with other vaccines in 7363 (62.3%) travelers. Local adverse reactions, mostly local pain, were reported by 5263 (47.5%) subjects. Systemic reactions were reported by 4891 subjects (41.4%) and were most frequently fatigue, myalgia, and flu-like symptoms. The majority of adverse events manifested in the second week after vaccination (median 8 days) and were mostly limited to a duration of 1\u20133 days. A macular exanthema was described by 1844 subjects (15.6%), typically during the second week after the vaccination. Conclusions: Side effects were frequently reported but generally well tolerated. Age groups above 50 years showed a decline in reactogenicity. Co-vaccination was frequent and led to an increase in systemic adverse events. Denominator data of the study population suggest a strong reporting bias towards adverse events. This survey adds evidence of the chronology and characteristics of adverse events associated with TAK-003 and may support decision making when vaccinating dengue-na\u00efve travelers.<\/jats:p>","DOI":"10.3390\/tropicalmed10120352","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:22:58Z","timestamp":1765905778000},"page":"352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Tolerability of the Dengue Vaccine TAK-003 (Qdenga\u00ae) in German Travelers: The Results of a Prospective Survey"],"prefix":"10.3390","volume":"10","author":[{"given":"Tomas","family":"Jelinek","sequence":"first","affiliation":[{"name":"Berlin Centre for Travel & Tropical Medicine, Friedrichstrasse 134, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Kramm","sequence":"additional","affiliation":[{"name":"Berlin Centre for Travel & Tropical Medicine, Friedrichstrasse 134, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Wagner","sequence":"additional","affiliation":[{"name":"Berlin Centre for Travel & Tropical Medicine, Friedrichstrasse 134, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jelinek","sequence":"additional","affiliation":[{"name":"Berlin Centre for Travel & Tropical Medicine, Friedrichstrasse 134, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhang, W.X., Zhao, T.Y., Wang, C.C., He, Y., Lu, H.-Z., Zhang, H.-T., Wang, L.-M., Zhang, M., Li, C.-X., and Deng, S.-Q. (2025). Assessing the global dengue burden: Incidence, mortality, and disability trends over three decades. PLoS Negl. Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0012932"},{"key":"ref_2","unstructured":"European Centre for Disease Prevention and Control (2025, May 14). Dengue Worldwide Overview. Available online: https:\/\/www.ecdc.europa.eu\/en\/dengue-monthly."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_4","unstructured":"World Health Organization (2018). Dengue vaccine: WHO position paper\u2014September 2018. Wkly. Epidemiol. Rec., 93, 457\u2013476."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2025, May 14). Questionstar Knowledge Base. Available online: https:\/\/questionstar.com\/knowledge-base\/help\/introduction\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"taaf004","DOI":"10.1093\/jtm\/taaf004","article-title":"First clinical experiences with the tetravalent live vaccine against dengue (Qdenga\u00ae) in travellers: A multicentric TravVacNet study in Germany","volume":"32","author":"Rothe","year":"2025","journal-title":"J. Travel Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E1350","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: A new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","first-page":"3","article-title":"STIKO-Empfehlung und wissenschaftliche Begr\u00fcndung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga","volume":"48","author":"Kling","year":"2023","journal-title":"Epid Bull."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S1473-3099(20)30601-0","article-title":"Risk predictors of progression to severe disease during the febrile phase of dengue: A systematic review and meta-analysis","volume":"21","author":"Sangkaew","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tricou, V., Essink, B., Ervin, J.E., Turner, M., Escudero, I., Rauscher, M., Brose, M., Lefevre, I., Borkowski, A., and Wallace, D. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS Negl. Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0011124"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2023.01.007","article-title":"A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"ref_13","first-page":"112","article-title":"Tolerability of multiple vaccinations in travel medicine","volume":"10","author":"Jelinek","year":"2003","journal-title":"J. Travel Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"tay026","DOI":"10.1093\/jtm\/tay026","article-title":"Adverse events in vaccinations for travelers\u2014A 1-year prospective survey in a travel clinic in Germany","volume":"25","author":"Slesak","year":"2018","journal-title":"J. Travel Med."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/12\/352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T05:22:06Z","timestamp":1766035326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/10\/12\/352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["tropicalmed10120352"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed10120352","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}